Blog

Sanfilippo syndrome gene therapy could be filed in US next year, Abeona – BioPharma-Reporter.com

Sanfilippo syndrome gene therapy could be filed in US next year, Abeona
BioPharma-Reporter.com
But while pharma firms such as Shire, Alexion and BioMarin are investigating enzyme replacement therapies, Abeona says its gene therapy candidate ABO-102 could offer patients a cure delivered by a single injection. In February, Abeona presented

2017-04-11 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.